Commitments, Contingencies and Collaboration and License Agreements - Narrative (Details) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 shares	Dec. 31, 2020 shares	Aug. 09, 2022	Mar. 31, 2022 USD ($)	Nov. 30, 2021 USD ($) ft²	May 31, 2021 USD ($)	Feb. 28, 2021 USD ($)	Aug. 31, 2020	Aug. 03, 2020 USD ($)
Other Commitments [Line Items]
Area of industrial space | ft²										63,000
Right-of-use assets	$ 8,484		$ 8,484		$ 9,308
Operating lease liability	9,724		9,724
Research and development	18,170	$ 18,828	48,759	$ 46,416
Peptidream, Inc. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Other Commitments [Line Items]
Research term								4 years						2 years
Research term extension														1 year
Warrant or right issuable as a percentage of fully diluted equity														5.00%
Amounts incurred or paid			0
Term of agreement														10 years
Right to terminate term														60 days
Issuance of common stock for license rights (in shares) | shares					851,943	286,656	1,187,980
Research and development		6,500		6,500
Peptidream, Inc. | Specified Development Regulatory Milestone Member | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Other Commitments [Line Items]
Asset acquisition milestone amount														$ 380,000
Nimble Therapeutics, Inc. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Other Commitments [Line Items]
Right to terminate term												90 days
Research and development	0	100	200	300
Upfront payment												$ 800
Unamortized balance	0		0
Nimble Therapeutics, Inc. | Discovery, Development and Sales Milestone | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Other Commitments [Line Items]
Aggregate payments												201,700
Nimble Therapeutics, Inc. | Discovery, Development and First Comercial Sales Milestone | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Other Commitments [Line Items]
Aggregate payments												$ 897,500
Ablaze Pharmaceuticals | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Other Commitments [Line Items]
Right to terminate term												60 days
Upfront payment												$ 0
Maximum payments, per product											$ 70,000
Niowave, Inc | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Other Commitments [Line Items]
Research term											20 years
Asset acquisition milestone amount											$ 10,000
Right to terminate term												6 months
Research and development	0	0	0	1,700
Unamortized balance	0		0		$ 0
Milestone payments	0	$ 0	0	$ 1,500
Milestones payable	0		0		$ 5,500
Office And Laboratory
Other Commitments [Line Items]
Lease term													5 years
Office And Laboratory | Standby Letters of Credit
Other Commitments [Line Items]
Maximum borrowing capacity	$ 100		$ 100
Land
Other Commitments [Line Items]
Lease term										5 years
Right-of-use assets									$ 2,300
Operating lease liability									$ 2,400
Land | Letter of Credit
Other Commitments [Line Items]
Maximum borrowing capacity										$ 200